Document is current
Any future updates will be listed below
-
Authors
Wang, Lijun
Wu, Peitao
Liu, Yi
Patel, Divya C
Leonard, Thomas B
Zhao, Hongyu
-
Funding
Funding for this research was provided by:
The IPF-PRO/ILD-PRO Registry is supported by Boehringer Ingelheim Pharmaceuticals, Inc and run in collaboration with the Duke Clinical Research Institute and enrolling centers. (N/A, N/A, N/A, N/A, N/A, N/A)
- License Information
-
More Information
Article History
Received: 26 June 2024
Accepted: 15 October 2024
First Online: 23 October 2024
Declarations
:
: The IPF-PRO Registry study obtained ethics approval at the data coordinating center (Duke Clinical Research Institute, Duke Institutional Review Board Protocol Number Pro00046131) and at every enrolling center (listed in the Acknowledgments). Additionally, ethics approval was granted by the Duke Institutional Review Board Protocol Number Pro00082241 to use the biosamples obtained as part of the IPF-PRO Registry for the analyses presented in this paper. All participants gave informed consent to participate in the IPF-PRO Registry.
: Not applicable.
: Lijun Wang, Peitao Wu, Yi Liu, and Divya C Patel are employees of Boehringer Ingelheim Pharmaceuticals, Inc. Thomas B Leonard was an employee of Boehringer Ingelheim Pharmaceuticals, Inc at the time that these analyses were planned and conducted. Hongyu Zhao has no competing interests other than the funding of this project by Boehringer Ingelheim Pharmaceuticals, Inc.
